This company listing is no longer active
0C1 Stock Overview
A clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Atreca, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.27 |
| 52 Week High | US$0.34 |
| 52 Week Low | US$0.19 |
| Beta | 1.09 |
| 11 Month Change | 0% |
| 3 Month Change | 7.20% |
| 1 Year Change | n/a |
| 33 Year Change | -97.25% |
| 5 Year Change | n/a |
| Change since IPO | -98.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0C1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.8% | 0.8% |
| 1Y | n/a | -18.3% | 8.6% |
Return vs Industry: Insufficient data to determine how 0C1 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 0C1 performed against the German Market.
Price Volatility
| 0C1 volatility | |
|---|---|
| 0C1 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0C1 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0C1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 90 | John Orwin | www.atreca.com |
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company’s ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria.
Atreca, Inc. Fundamentals Summary
| 0C1 fundamental statistics | |
|---|---|
| Market cap | €2.83m |
| Earnings (TTM) | -€91.85m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs 0C1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0C1 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$97.76m |
| Earnings | -US$97.76m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.47 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 0C1 perform over the long term?
See historical performance and comparison